Powder: -20°C for 3 years | In solvent: -80°C for 1 year
A3373 is a novel inhibitor targeting both Phospholipase D1 (PLD1) and Phospholipase D2 (PLD2), demonstrating half maximal inhibitory concentrations (IC50) of 325 nM for PLD1 and 15.15μM for PLD2. This compound effectively suppresses lipopolysaccharide (LPS)-induced immune responses and is implicated in key processes of autoimmune arthritis, bone demineralization, and osteoclastogenesis [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | A3373 is a novel inhibitor targeting both Phospholipase D1 (PLD1) and Phospholipase D2 (PLD2), demonstrating half maximal inhibitory concentrations (IC50) of 325 nM for PLD1 and 15.15μM for PLD2. This compound effectively suppresses lipopolysaccharide (LPS)-induced immune responses and is implicated in key processes of autoimmune arthritis, bone demineralization, and osteoclastogenesis [1] [2]. |
Molecular Weight | N/A |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
A3373 Metabolism Phospholipase inhibitor inhibit